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Osteoporosis is the most common and serious age-related skeletal disorder, characterized by a low bone mass and bone
microarchitectural deterioration, with a consequent increase in bone fragility and susceptibility to spontaneous fractures, and
it represents a major worldwide health care problem with important implications for health care costs, morbidity and mortality.
Today is well accepted that osteoporosis is a multifactorial disorder caused by the interaction between environment and genes that
singularly exert modest effects on bone mass and other aspects of bone strength and fracture risk. The individuation of genetic
factors responsible for osteoporosis predisposition and development is fundamental for the disease prevention and for the setting
of novel therapies, before fracture occurrence. In the last decades the interest of the Scientific Community has been concentrated
in the understanding the genetic bases of this disease but with controversial and/or inconclusive results. This review tries to
summarize data on the most representative osteoporosis candidate genes. Moreover, since recently osteoporosis and cardiovascular
diseases have shown to share common physiopathological mechanisms, this review also provides information on the current
understanding of osteoporosis and cardiovascular diseases common genetic bases.
1. Introduction
Osteoporosis is the most common age-related skeletal
chronic disorder, characterized by reduced bone mass,
deterioration of bone micro-architecture and increased risk
of low-trauma fractures. Fragility fractures are the endpoint
of osteoporosis and represent the major cause of morbidity
and mortality. With the constant growing age of population,
not only in developed countries but also in South America,
Asia, and Africa, osteoporosis is becoming more and more
a worldwide major public health problem. Today over two
hundreds millions people worldwide and the thirty per
cent of all postmenopausal women in USA and Europe
are affected by osteoporosis. At least 40% of all affected
women and 15–30% of all affected men will suffer a fragility
fracture during their lifetime. The individuation of factors
responsible for osteoporosis predisposition and development
is fundamental for disease prevention and for setting of novel
therapies.
According to the International Osteoporosis Foundation
(IOF) guidelines, osteoporosis risk factors can be divided
into two main classes: (1) modifiable risks that depend
principally on lifestyle and nutrition habits and can be
modified and (2) fixed risks that are innate and cannot
be modified. Main osteoporosis risk factors are depicted in
Table 1.
Today Scientific Community agrees that osteoporosis is
a complex multifactorial disorder caused by the interaction
between environmental factors and genes that singularly
exert modest effects on bone metabolism and fracture risk.
Studies on osteoporosis sibs and families demonstrated
that genetic factors are responsible for about 60–85% of
inter-individual variability of bone mineral density (BMD)
[1, 2], and this effect appears to persist even in the late
decades of life. BMD heritability varies between different
skeletal sites [3]. Also fragility fracture risk seems to have
a genetic component; family history of fracture has been
shown in some epidemiological studies as a risk factor for
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Table 1: Main risk factors for osteoporosis.
Osteoporosis modifiable
risks
Osteoporosis fixed risks
(i) Alchool (i) Age
(ii) Smoking (ii) Ethnicity
(iii) Low body mass index (iii) Female gender
(iv) Poor nutrition (iv) Family history of fractures
(v) Eating disorders (v) Previous fractures
(vi) Insufficient physical
activity
(vi) Menopause/hysterectomy
(vii) Low dietary calcium
intake
(vii) Hormonal status
(viii) Vitamin D deficiency
(viii) Long-term glucocorticoid
therapy
(ix) Frequent falls
(ix) Primary/secondary
hypogonadism in men
fractures [4, 5]. Interestingly, the heritability of fractures
has been shown to be independent of BMD and maybe
influenced by other factors such as bone geometry, bone
turnover or the risk of falling. However, the heritability of
fractures seems to decrease with age maybe as environmental
factors become more important. Other bone features such as
quantitative ultrasound properties, femoral neck geometry,
bone turnover markers range have been demonstrated to be
under the control of genetic factors [6, 7]. Except for some
rare Mendelian monogenic inherited osteoporosis forms
(osteoporosis associated with estrogen deficiency due to
inactivating mutation of the aromatase gene (CYP19) [8]
or associated with estrogen resistance due to inactivating
mutation of the estrogen receptor alpha (ERα) gene [9], and
autosomal recessive osteoporosis pseudoglioma caused by
inactivating mutation of lipoprotein receptor-related protein
5 (LRP5) [10], classic age-related osteoporosis is a multifac-
torial heterogeneous disorder and, to date, its exact genetic
bases are still unknown. In fact, bonemetabolism is regulated
by several genes, some exerting a high degree of influence
(major genes) and other, even more numerous, exerting
minor effects (minor genes). Due to the complex biology
of the skeleton, putative osteoporosis candidate genes are
very numerous and the number of genes identified to be
involved in bone metabolism is constantly increasing. They
include genes involved in the regulation of bone and calcium
metabolism, such as those encoding for calciotrophic and
sex hormones and their receptors, for bone matrix proteins,
for cytokines, growth factors and local mediators and their
receptors, and for proteins involved in molecular pathways
of bone cells. Principal osteoporosis candidate genes are
described in Table 2.
Moreover, the presence of epigenetic regulative factors,
gene-gene and gene-environment interactions complicate
the situation. Different genetic and environmental factors
may result in the same osteoporotic phenotype and it is
also possible that some individuals having one or more
predisposing alleles and genetically at risk of osteoporosis
never become osteoporotic or, controversially, individuals
with no predisposing alleles may develop osteoporosis with
age due to non-genetic factors.
Candidate gene association studies have identified several
polymorphisms associated to BMD, bone characteristics and
fragility fracture risk. However, these association studies
generated conflicting results may be due to inadequate
population sampling, ethnicity, gender, age, confounding
factors, lack of standardized genotyping methods, gene-gene
interactions, linkage disequilibrium with other trait-causing
polymorphisms in a nearby locus, epigenetic and/or post-
transcriptional gene expression regulation (i.e., microRNAs)
and gene-environment interactions. Retrospective meta-
analyses, including several different association studies,
and multicentric studies on large and well characterized
populations are both helpful in reducing these issues and
increasing the power of statistical associations. Several
reviews on genetics of osteoporosis tried to summarize the
most representative osteoporosis association studies [11–15].
Some of the most important and most studied osteo-
porosis candidate genes will be briefly discussed below, with
specific focus on the results of the European Genomos
study. The Genomos (Genetic Markers for Osteoporosis)
study is an European multicentric consortium that collected
over 20 000 Caucasian subjects (women and men) from
several European centers, using prospective genotyping with
cross-center standardization, for the study of osteoporosis
candidate genes.
For years osteoporosis and cardiovascular diseases
(CVDs) have been considered as two independent conse-
quences of aging, however, recent evidences support an
association between these two diseases, indicating common
physiopathological mechanisms, and maybe genetic bases.
2. Osteoporosis and Cardiovascular Diseases
Some studies have reported associations between age-related
CVDs and bone loss and have indicated common etiologies
for CVDs and osteoporotic fractures with a substantially
increased risk of hip fractures in women after the diagnosis
of a CVD [16–19].
More than 90% of atherosclerosis fatty plaques undergo
calcification. Now it is well assessed that calciummetabolism
has a central role both in bone mineralization and on the risk
of arteriosclerosis development and progression, since regu-
latory factors of bone cells functions can also affect vascular
calcification. Osteoprotegerin (OPG) and receptor activator
of nuclear factor kappa B ligand (RANKL) regulate osteoclast
activation and function but are also involved in the vascular
calcification process and atherosclerosis [20, 21]. Bone
morphogenetic protein (BMP2) is involved in osteoblastic
differentiation by the stimulation of Runx2 expression; in
humans, atherosclerotic lesions show an increased expression
of BMP2 and Runx2 with respect to normal arteries [22]
and this may be responsible for arteries wall calcification.
Some others biological and environmental factors seem to be
involved both in altered bone mineralization and in vascular
calcifications, such as vitamin D insufficiency, low calcium
intake, estrogen deficiency, chronic inflammation, oxidative
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stress, dyslipidemia, high dietary fat intake, smoking, low
physical activity. Elderly people present with calcium and
vitamin D deficiency that could contribute to calcium
mobilization from bones with consequently higher risk of
fractures and of severe vessels and arteries calcification. At
the same time the age-related estrogen deficiency may induce
the increase of pro-inflammatory cytokines (IL1, IL6 and
TNFα) that enhances the expression of adhesion molecules
on leukocytes and endothelial cells favoring the progression
of atherosclerosis plaques. Estrogen deficiency also induces
the decrease of OPG with subsequent calcium mobilization
from bones and risk of calcification of atherosclerosis
plaques. Last, estrogen deficiency induces a reduction of
production of nitric oxide which has athero-protective effects
but also plays a role in osteoblast function and regulates
the endothelial function of bonemicrocirculation.Moreover,
elevated LDL and low HDL cholesterol, suspected to be
responsible for atherosclerosis, are associated also with
low BMD and with vertebral fractures in postmenopausal
women [23]. The altered lipid metabolism is associated with
both bone remodeling and atherosclerosis process [22] and
this may explain, in part, the coexistence of atherosclerosis
and osteoporosis in patients with dyslipidemia.
Animal, clinical and epidemiological studies suggest
that high blood pressure is associated with abnormalities
of calcium metabolism, leading to increased calcium loss,
increased movement of calcium from bone and long-term
risk of bone demineralization and osteoporosis [24–26].
Metabolic studies in hypertensive rats showed that associ-
ated hypercalciuria and secondary activation of parathyroid
glands induced a reduced growth and a decreased bone
mineral content later in life [27, 28]. The mechanisms by
which this occurs are probably due to a defect in the kidney
ability to handle calcium. Moreover, cross-sectional studies
[29, 30] in humans have shown an inverse positive asso-
ciation between blood pressure and bone mineral density,
supporting a possible correlation between hypertension and
osteoporosis.
Last, recent evidences of the action of bone antiresorptive
drugs also on the reduction of CVDs risk and evidences of the
positive effect of statins, antihypertensive drugs and insulin
on bone mass increase [22, 31–33] suggest that osteoporosis
and CVDs share common physiopathological molecular
pathways. Bisphosphonates are potent antiresorptive agents
widely used in osteoporosis treatment and in prevention
of fracture risk. Experimental studies on animal models
demonstrated that bisphosphonates also inhibit arterial
and cardiac calcification in mice [34] and prevent foam
cell formation by inhibiting LDL uptake and macrophages
replication [33]. Raloxifene is a selective estrogen receptor
modulator prescribed for both the prevention and treatment
of osteoporosis and with a proven efficacy in the reduction of
risk of fragility fractures. Raloxifene seems to have favorable
effects on LDL cholesterol level and risk of coronary heart
disease and it improves vascular endothelial function in post-
menopausal women [35, 36]. The results from the MORE
(Multiple Outcomes of Raloxifene Evaluation) randomized
trial made possible to decipher the effects of raloxifene
on cardiovascular events in osteoporotic postmenopausal
women, evidencing that raloxifene therapy for 4 years did
not significantly affect the risk of cardiovascular events in
the overall studied population but it significantly reduced
this risk in the subpopulation of women with increased
cardiovascular risk [37]. Statins reduce cardiovascular mor-
tality through the regression of coronary calcification and
the reduction of LDL cholesterol levels in patients with
dyslipidemia. These hypolipidemic drugs have also been
associated to increased bone mineralization in mice [38]
and in patients with osteoporosis [39] and with a reduction
of fracture incidence. Last, recent clinical studies indicated
that beta blockers and antihypertension drugs would reduce
the risk of fragility fractures in the elderly population [40].
Moreover, in a rodent model angiotensin II type 1 and
2 receptor blockers (ARB) widely used antihypertensive
agents, were shown to enhance bone mass through both
the increase of osteoblast activity and the suppression of
osteoclast activity [41]. Recently, a preventive effect of
angiotensin II type 1 receptor blocker on osteoporosis has
been reported but these data need confirmation [42]. The
fact that all these drugs are effective on both osteoporosis and
CVDs suggests a possible link between vascular and skeletal
systems. Therefore, it is priority to establish to what extent
treatments for osteoporosis are effective and beneficial for
CVDs and vice versa, as well as to comprehend the exact
physiopathological mechanisms shared by these diseases.
According to the current knowledge, further specific
studies are necessary to better define the relationship
between osteoporosis and CVDs and to identify common
risk factors and genetic determinants.
3. Vitamin D Receptor Gene (VDR)
Since the important role of vitamin D in the regulation
of calcium homeostasis and bone metabolism, vitamin D
receptor (VDR) gene has been the first candidate gene to be
analyzed in association studies by Morrison at al. in 1994
[43] and it was proposed as a major locus for genetic effects
on bone metabolism. Principal analyzed polymorphisms are
the BsmI, ApaI, and TaqI polymorphisms in the 3′ UTR of
the gene, the FokI polymorphism in exon 2 (that creates
an alternative initiation traduction codon) and the Cdx2
polymorphism in the promoter region of the gene. During
the last two decades, several association studies have been
performed but with conflicting data. Recent data seem to
indicate that association between VDR polymophisms and
bone mass is rather weak and the clinical impact of these
variants remains unclear. Given the extent of published
data on this gene and the non-concording results, interest
now focuses on meta-analyses rather than single association
studies alone. A haplotype meta-analysis by Thakkinstian
et al. [44] evidenced that VDR single polymorphisms were
not significantly associated to osteoporosis while Bat and
BAt haplotypes were significantly associated, demonstrating
the importance of haplotype studies rather than single
polymorphism studies.
The Genomos study collected 26,242 Caucasian partici-
pants (18,405 women) and evaluated the association between
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Cdx2, FokI, BsmI, ApaI, and TaqI polymorphisms with the
DEXA-measure femoral neck and lumbar spine BMD and
fractures, concluding that the FokI, BsmI, ApaI, and TaqI
polymorphisms are not associated with BMD variation or
with fractures while the “A” allele of the Cdx2 polymorphism
is associated with a reduced risk of vertebral fractures
[45].
VDR is involved in vascular smooth muscle cell growth
and in the regulation of calcium homeostasis and could
therefore be involved in vascular plaques instability and
calcification, thus, VDR polymorphisms may be associated
with different risk for CVDs. In a study by Van Shooten et
al. [46] the bb genotype of the VDR gene appeared to be
predictive of severe coronary artery disease (CAD). The bb
genotype is associated with low levels of circulating active
form of vitamin D (calcitriol) [43], thus, results from this
study seem to agree with previous finding of an inverse
association between circulating calcitriol and CAD [47, 48].
The genetic association between VDR polymorphisms and
CAD risk was not confirmed by a study in a Chinese
population [49].
4. Estrogen Receptors Alpha and
Beta Genes (ERα and ERβ)
Estrogens exert important effects on bone mass acquisition
and maintenance. A rare case of a 28-year-old man with
estrogen resistance and juvenile osteoporosis due to a
nonsense inactivating point mutation in exon 2 of the ERα
gene has been described [9]. Patient presented with unfused
epiphyses and continuing linear growth in adulthood, indi-
cating that estrogen is important for normal skeletal growth
and bone development and mineralization in men as well
as women. Genes encoding for estrogen receptors have been
widely investigated in osteoporosis association studies. Most
studies have focused on the (TA)n repeat microsatellite in
the promoter region and on the PvuII and XbaI single
nucleotide polymorphisms (SNPs) in the intron 1 of the ERα
gene. However, these studies generated conflicting results,
suggesting the needing of large-scale investigations and
analysis standardization. A meta-analysis by Ioannidis et al.
[50] seemed to indicate no significant association between
single ERα polymorphisms with BMD, while a significant
reduction of fracture risk was associated to the XX genotype.
Conversely, when ERα polymorphisms are analyzed together
as haplotypes [51], significant associations of haplotypes
with spinal BMD, decreased vertebral spine bone area and
increased risk for spinal fracture were found in women, but
not in men. This study also evidenced that ERα-dependent
fracture risk is independent of BMD and bone area.
The Genomos study collected 18 917 individuals (14,622
women) and evaluated the association of the three common
ERα polymorphisms with the DEXA-measured femoral
neck and lumbar spine BMD and with fractures [52]. The
study evidenced that ERα polymorphisms exert only small
effects on BMD. Conversely, the XX genotype resulted to
be associated with a 20% reduction in fracture risk by
mechanisms independent of BMD.
However, to date most association studies on ERα gene
have evaluated the association of its polymorphisms with
BMD and fracture risk but not with bone structural and
geometric properties. Recently, Cepollaro et al. [53] have
evaluated the influence of XbaI and PvuII polymorphisms
on structural and geometric bone parameters assessed by
pQCT at the tibia in 541 Italian women and 449 Italian men.
The study evidenced a significant association between the
PP genotype of PvuII and higher values of tibial cortical
thickness in male subjects. This result indicated a role for
ERα gene in the control of tibia bone geometry and could
explain the mechanism by which ERα gene polymorphisms
influence fracture risk independently of BMD.
ERβ gene has been less studied in osteoporosis associ-
ation studies since its role on bone metabolism is not yet
completely known. ERβ seems to have a role in mediating
estrogen effect on bone growth and bone size but not on
BMD [54]. A (CA)n repeat microsatellite polymorphism in
the promoter region has been associated with BMD in Asian
[55, 56] and Caucasian [57] populations. No meta-analysis
of ERβ association studies is available so far.
Estrogens have vasodilatatory, antiinflammatory and
antiproliferative effects on the cardiovascular system and
they have been reported to provide protection against CAD
in postmenopausal women [58]. Lu et al. [59] associated
the novel −1989T/G polymorphism in the ERα promoter B
with CAD risk, concluding that the G/G genotype may be
an independent predictor for CAD in patients with familiar
hypercholesterolemia. In addition, they found that the long
number (>17) of (TA)n repeat in the ERα promoter region
was significantly higher in postmenopausal women with
CAD than in those without CAD, but not in men. Pollak
et al. [60] confirmed this result and found an association
between homozygote genotype for long alleles (>18) and a
significantly higher angiographic severity of CAD in young
patients. Alevizaki et al. [61] found that ERα PuII and
XbaI polymorphisms may influence the severity of CAD in
women, associating the C allele of PvuII and the G allele
of XbaI with a higher number of arteries with a significant
stenosis in the coronary angiography.
5. Collagen Type I α1 Gene (COLIA1)
COLI1A1 gene encodes for the α1 chain of collagen type I
that is the principal proteic component of bone extracellular
matrix, thus, this gene is an important candidate for osteo-
porosis risk. Several association studies have been conducted
on a polymorphism in intron 1, a G/T substitution that
creates a binding site for the transcription factor Sp1.
The ss (T/T) genotype has been associated with reduced
BMD [62, 63], increased age-related bone loss [64, 65],
increased femoral neck angle [66], an impaired ability of
osteoblast-like cells to form mineralized bone nodules in
vitro and with abnormalities of bone mineralization in vivo
[67] and a higher risk of fracture due to altered bone
density and quality [68]. In general, association studies on
this gene demonstrated a positive correlation between SS
(G/G) genotype and reduced fracture risk even with lack of
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association with BMD values. Ameta-analysis evidenced that
different Sp1 alleles are associated with modest variation in
BMD but with significant changes in fracture risk [69]. The
T allele is associated with an abnormally increased synthesis
of collagen I α1 chain generating an imbalance between the
α1 and α2 chains and a reduction of bone strength and bone
matrix mineralization [67].
The Genomos study collected standardized data on
20,786 individuals and evaluated association of the Sp1
polymorphism with the DEXA-measured femoral neck and
lumbar spine BMD and with fractures [70]. The s allele
resulted to be associated with recessive-inherited reduced
BMD. However, this association was quite weak. Authors
also found a modest association of the s allele with vertebral
fractures, particularly in women, and hypothesized that
this allele could predispose to incidental vertebral fractures
independently of BMD.
6. Transforming Growth Factor β1 (TGFβ1)
TGFβ1gene encodes a local growth factor that is widely
expressed by bone cells and it is involved in the regulation
of bone turnover [71–73]. This gene has been analyzed as
a possible osteoporosis candidate gene; principal investi-
gated polymorphisms are located in the promoter region
(−1348C/T and −509C/T) and in the exon 1 (29T/C
Leu10Pro and 74G/C Arg25Pro). Several studies have associ-
ated variants in this gene with BMD variation and/or fragility
fractures risk [74–80], but none of them have investigated the
effects of TGFβ1 haplotypes.
The Genomos study performed a wide standardized
analysis including 28 924 participants from 10 European
centers [81]. The study genotyped five polymorphisms of
TGFβ1 gene (two located in the promoter region, two located
in the exon 1 and one located in exon 5) and associated them
with DEXA-measured BMD of lumbar spine and femoral
neck and with fractures. None of the polymorphisms or
haplotypes resulted to be associated to BMD variations or
to affect the overall risk of fractures. A weak association was
detected between carriers of the rare 788T allele of the 788
C/T polymorphism (Thr263Ile) in exon 5 and the risk of
incident vertebral fractures.
TGFβ seems to have contrasting functions on cardio-
vascular system. Some studies reported a protective effect
of TGFβ by reducing the risk of CVDs [82–85], while
others described TGFβ as inducing or facilitating CVDs
such as vascular stenosis and thrombogenesis [86, 87]. The
Arg25Pro polymorphism in exon 1 has been associated with
different risk of essential hypertension in Russian male
individuals [88], with variation in systemic blood pressure
in essential hypertensive patients [89] and with different
risk of myocardial infarction or hypertension in Caucasian
patients [90], but no correlation has been found between
this polymorphism and the risk of myocardial infarction
and stroke [91], the risk of CAD in Caucasian patients
[92] and with the severity of CAD and the occurrence of
myocardial infarction or hypertension in Australian patients
[93]. The Leu10Pro polymorphism in exon 1 has been
associated with susceptibility to myocardial infarction in
a Japanese population [94], with clinical characteristics of
hypertension [95] and with the risk of stroke in an elderly
Caucasian population [91], but not with the risk of myocar-
dial infarction in the same elderly Caucasian population
[91].
7. Low-Density Lipoprotein Receptor-Related
Protein 5 and 6 (LRP5 and LRP6)
LRP5 and its related homologue LRP6 are cell-membrane
coreceptors for Wnt proteins an the Wnt/beta catenin
signalin pathway, that controls osteoblast activity and bone
formation. LRP5 gene has a clear role in rare bone diseases
and also in normal variation in peak BMD.
Inactivating mutations of LRP5 lead to osteoporosis
pseudoglyoma [96] while activating mutations result in high
bone mass phenotypes [97, 98].
Point mutations in LRP6 gene cause abnormal formation
of the axial skeleton and a low bone mass phenotype in mice
[99].
Thus, common variants in LRP5 and LRP6 genes may
contribute to normal population variance in human bone
metabolism, and these two genes have been recently pro-
posed and analyzed as putative osteoporosis candidate genes.
Two studies [100, 101] have demonstrated an association
between LRP5 variants and bone mass in human popula-
tions. Particularly, Ferrari et al. [100] found an association
between 2047 G/A substitution (Val667Met) in exon 9 and
bone mineral content at lumbar spine, bone area and with
stature in men, but not in women.
A study by van Meurs et al. [102] analyzed the role of
four variants of the LRP5 gene and one aminoacid variant
of the LRP6 gene in determining BMD, bone geometry
and fracture risk. Authors found that the 1330Val allele
(Ala1330Val polymorphism) of the LRP5 gene was associated
with a decreased BMD at lumbar spine and femoral neck and
with reduced vertebral body size and femoral neck width in
men. Male carriers of the 1330Val allele had a 60% increased
risk for fragility fractures. A borderline association of the
LRP6 Ile1062Val polymorphism with height and vertebral
body size was observed in men. Males carriers of the 1062Val
allele had a 60% higher risk of fractures. In women all these
association were weaker than in men.
All these studies indicated that LRP5 and LRP6 associa-
tions with bone phenotypes are sex specific.
The Genomos study collected and analyzed 37,534 Cau-
casian individuals from Europe andNorth America and asso-
ciated DEXA-measured BMD at lumbar spine and femoral
neck and fracture risk with Val667Met and Ala1330Val
polymorphisms of the LRP5 gene and with Ile1062Val
polymorphism of the LRP6 gene [103]. The Met667 and
Val1330 alleles were both associated with reduced spinal
and femoral BMD and with increased risk of vertebral or
total fractures. Haplotype analysis indicated thatMet667 and
Val1330 variants affected BMD independently. Conversely,
the LRP6 Ile1062Val polymorphism was not associated with
any osteoporotic phenotype.
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No studies on the association of LRP5 and LRP6
polymorphisms with CVDs risk are available so far.
8. Aromatase Gene (CYP19A1)
Aromatase enzyme catalyses the conversion of androgens
to estrogens. Inactivating mutations of the CYP19A1 gene
have been associated, in both sexes, with an increased bone
turnover and consequently with a decreased BMD [8].
A microsatellite tetranucleotide (TTTA)n repeat poly-
morphism in intron 4 was associated to osteoporosis risk
[104]. Analysis of polymorphism in a postmenopausal
cohort of Italian women associated the (TTTA)12 allele with
a protective action versus osteoporosis development. Women
with high number of repeats (>11) showed higher lumbar
BMD values than women with low number of repeats (from
8 to 11). However, the molecular mechanism that can explain
association between aromatase activity and (TTTA)n repeat
is still unknown.
Aromatase has been hypothesized as one of the factor
affecting blood pressure and maybe a susceptibility gene
for hypertension. A study by Shimodaira et al. [105]
found an association between the rs700518 and rs10046
polymorphism, as well as a haplotype constructed with
rs1870049 and rs10046 polymorphisms, of CYP19A1 gene
with variation in systolic blood pressure and diastolic blood
pressure. Interestingly, the at risk genotypes of rs700518
and rs10046 showed a sex-dependent inverse relationship,
suggesting the possibility to use them as genetic markers
for gender-specific essential hypertension risk. Ramirez-lorca
et al. [106] confirmed that the rs10046 polymorphism may
be involved in the genetic regulation of blood pressure in
women. Another study by Letonja et al. [107] concluded
that in Caucasian subjects the (TTTA)n repeat polymor-
phism does not contribute to the genetic susceptibility to
CAD.
9. Insulin-Like Growth Factor I Gene (IGF-1)
IGF-1 exerts anabolic effects on BMD increasing synthesis
of collagen type I and osteocalcin and stimulating alkaline
phosphatase activity that results on both proliferation and
differentiation of osteoblasts. It is an essential factor during
childhood and adulthood in the regulation of trabecular and
cortical bone formation.
Association studies evaluated a (CA)n repeat in the pro-
moter region of the gene but with controversial results. The
presence of the 194-bp allele has been associated to higher
BMD and increased level of circulating IGF-1 in osteoporotic
Korean women with respect to healthy controls [108]. Low
levels of IGF-1 and a reduced BMD were associated to the
homozygote 192 bp allele in men with idiopatic osteoporosis
[109] and in Caucasian postmenopausal women [110].
However, a study on Japanese postmenopausal women [111],
a study on premenopausal Chinese women [112], and a study
on premenopausal Caucasian and Afro-American sibling
pairs [113] did not confirm the precedent results.
10. Interleukin 6 (IL6)
After menopause the increase of IL6 and other pro-
inflammatory cytokines production related to the estrogen
decrease has been associated to the extent of bone loss
[114]. The IL6 gene locus (7p21) has been associated with
BMD variations in postmenopausal women [115]. Two
polymorphisms (−572G/C and −174G/C) in the promoter
region of the IL6 gene have been associated to markers of
bone resorption in postmenopausal women [116, 117]. A
study of Ferrari et al. [118] evidenced that the G/G genotype
of the −174G/C polymorphism was associated to a lower
BMD with respect to the G/C and C/C genotypes in over
15-year postmenopausal women but not in premenopausal
women and in men. These results seem demonstrate that IL6
polymorphisms regulate bone mass only after menopause
with a molecular mechanism dependent on the estrogen
deficiency.
IL6 is a key mediator of inflammation and it has been
demonstrated to play an important role in the pathogenesis
of atherosclerosis and vascular diseases. Elevated concen-
trations of IL6 are predictive of future coronary events
in healthy individuals and of mortality in patients with
acute coronary disease. The −174G/C polymorphism in
the promoter region has been associated with variation
in IL6 production. Several studies have demonstrated that
this polymorphism is associated with risk of coronary
hearth disease in men [119–122], with the risk of ischemic
carebrovascular events [123], with carotid artery compliance,
systolic and diastolic blood pressure and serum high-
density lipoprotein cholesterol in men [124], ischaemic
stroke [125], number of severely stenosed coronary arteries
[126]. However, despite of numerous studies the role of this
polymorphism as a risk factor for CVDs remains inconsistent
[127, 128] and needs for further researches.
11. Other Candidate Genes
Other osteoporosis candidate genes have been studied even if
less extensively and with less conclusive results. They include
calcitonin receptor (CTR) [129–133], calcium sensing recep-
tor gene (CaSR) [134–136], androgen receptor (AR) [137],
parathyroid hormone receptor (PTHR1) [138], sclerotin
(SOST) [139], bone morphogenetic protein 2 (BMP2) [140],
osteoprotegerin (OPG) [141, 142], and so forth. All these
gene require confirmation on larger cohorts.
12. Genome-Wide Association Studies
The complete sequencing of human genome [143], the
results of the HapMap project [144] and the development
of novel chip technologies have opened novel avenues for
the identification of genetic loci, genes and/or polymor-
phisms associated with complex diseases such as osteoporo-
sis, through the application of genome-wide association
analyses. This approach has permitted the simultaneous
analysis of hundreds loci/genes along the human genome and
the identification of novel osteoporosis subsceptibility loci
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Table 3: QTLs identified and replicated in genome-wide linkage
studies for osteoporosis [145]. Asterisks indicate genetic region
associated also to clinical CVD events through genome-wide
association studies [147].
QTLs replicated
in at least two
studies
QTLs replicated in
at least three
studies
QTLs replicated in
at least five studies
- 2p21-24 - 13q31-34 - 1p36
- 2q33-37∗ - 17p11-13 - 1q21-24
- 3q12-26 - 4q31-34
- 4p15-16 - 12q23-24∗
- 5q33-35
- 6p21
- 8q24-qter
- 10q26
- 11q23-24
- 14q12-24
- 14q31-32
- 16p13
- 19p13-q13
- 21q22-qter∗
and/or genes that were not candidates based on the current
knowledge of the phatophysiology of bone metabolism and
osteoporosis. Over 60 quantitative trait loci (QTLs) have
been associated with bone metabolism and they were located
in all but chromosome Y [145]. A list of genetic loci identified
to be linked to bone metabolism through genome-wide
approaches, and replicated in at least two different studies,
are reported in Table 3. The first osteoporosis genome-wide
association study [146] associated 100,000 SNPs with BMD
values, bone ultrasound properties and hip geometry index.
Some weak associations with genetic markers within or
near known osteoporosis candidate genes (i.e., ERα, CYP19,
COLIA1, and LRP5) were detected.
Particularly, the application of genome-wide association
scan has allowed the identification of bone morphogenetic
protein 2 (BMP2) as a candidate gene for osteoporosis,
through the analysis of 207 osteoporotic families (1323 indi-
viduals) in Iceland and the subsequent followup association
analysis [140]. Recently, also the latent transforming growth
factor beta binding protein 2 (LTBP2) [148] and the signal
transducer and the activator of transcription 1 (STAT1) [149]
genes have been associated with osteoporotic phenotypes.
Given the extensive number of identified candidate loci
to date, and given the potential large number of genes
within these loci, the next step will be the refinement
of the significant loci and the identification of putative
candidate genes. Novel identified candidate genes have to
be confirmed by follow-up population-based association
studies and functional studies. Caution should be taken in
the interpretation of replication/confirmation of the results
since some genomic region could eventually be proven to be
a false positive.
The past few years have seen a significant increase in
the number of genetic loci associated with CVDs through
genome-wide association studies. Significant results have
been reported in a recent review [147].
13. Animal Models
Comparative genetics is helpful in the comprehension of
molecular mechanisms of bone remodeling and in the
searching for osteoporosis candidate genes. Studies in ani-
mals are essential because they allow breeding strategies
that cannot be performed in humans and they also pro-
vided extreme bone strength phenotypes that cannot be
measured in vivo in humans. Rodents and primates are
the most suitable models. Linkage studies in rats [150],
mice [151, 152] and primates [153] have permitted the
identification of numerous QTLs that regulate BMD and
other bone quality properties (shape, microstructure and
strength). Particularly, linkage analysis in mouse has allowed
the identification of Alox15 gene as a negative regulator of
BMD. The Alox15-knock-out mice presented an increased
BMD and the inhibition of Alox15 expression compensated
the ovariectomy-induced bone loss [154]. Recent studies
have shown that genetic variations in a human homologue
of Alox15 (ALOX12) accounted for approximately 3% of
the bone mass variation in humans [155, 156]. Moreover,
the using of knock-out and transgenic animal models for
the study of bone monogenic diseases has helped in the
identification of biologically relevant osteoporosis candidate
genes for association studies. These approaches also helped
in delivering biological function of a specific gene in bone
metabolism. An example is the LRP5 gene whose activating
or inactivating mutations have been demonstrated to be
responsible for opposite extreme bone phenotypes [10, 96–
98], using specific LRP5-mutated animal models.
14. Future Perspectives: the Pharmacogenetics
of Osteoporosis
A very novel area of the genetics of osteoporosis is the
pharmacogenetics of osteoporosis. Pharmacogenetics is the
application of genetic studies to predict the outcome of drug
treatments with respect to both beneficial and adverse events,
and it is particularly important in chronic diseases, such as
osteoporosis, that require long-term drug treatments and
for which alternative effective drug therapies are available.
Potentially pharmacogenetics of osteoporosis will allow clin-
icians to choose in advance the best treatment and the most
effective drug regimen based on patient genotype. However,
to date only few studies on the pharmacogenetics of osteo-
porosis have been published and no clinical applications are
available. Pharmacogenetic studies associated osteoporosis
candidate genes (VDR, ERα, ERβ, and COLIA1) with the
response to antiresorptive and antifracture agents such as
hormone replacement therapy, raloxifene and bisphospho-
nates [157] and found weak associations. Recently a study
by our Research Group [158] associated the A/C rs2297480
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polymorphism of the FDPS gene with the response to amino-
bisphosphonates in a cohort of Danish osteoporotic women.
All these studies suggested the possibility to use genetic
screening to tailor decisions about osteoporosis antifracture
treatment choice; however, all these preliminary data need
to be confirmed and validated by large-scale studies, by
prospective well-designed clinical trials and by functional
analyses.
Data from studies on pharmacogenetics of osteoporosis
would be useful also in the field of CVDs since there are
scientific evidences of the positive action of antiresorptive
drugs, such as bisphosphonates and raloxifene, on the
reduction of CVDs risk [22, 31–33].
15. Conclusions
The contribution of genetic factors to age-related chronic
diseases such as osteoporosis and CVDs is important. The
identification of genes that contribute to the pathogenesis
of such disorders has potential public health, clinic and
therapeutic implications. However, since osteoporosis is
a complex multifactorial disease, the association studies
performed to date presented with non-concluding or con-
flicting results. Now it is clear that a single SNP exerts
less than 1–3% of effect in the determination of bone
metabolism. Only large-scale standardized studies in well-
characterized and homogenous populations and the study
of haplotypes and/or multiple SNPs and/or genes might
help in a better understanding of genetic factors under-
lying bone phenotypes heritability and calcium and lipid
metabolism regulation. Moreover, technological advances
such as genome-wide association scan will help in identifying
novel candidate loci and/or genes, in validating the role of
candidate gene polymorphisms and in analyzing hundreds
of SNPs simultaneously.
However, genetic epidemiology association studies did
not tell how genes contribute to the disease, thus, functional
genomic studies, large-scale gene expression studies and
proteomic studies are fundamental for the comprehension of
molecular and cellular mechanisms regulating bone and car-
diovascular pathophysiology. The aim of functional genetics
is not only to collect information about single gene functions
but also to understand how biological component work
together to regulate bone metabolism and cardiovascular
system functionality. The great challenge of genetics of
osteoporosis and cardiovascular diseases will be not only
identifying the responsible genes but also understanding
how these genes act and how they are influenced by other
biological and/or environmental factors.
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